Emergent BioSolutions: The path to re-emergence

Published on :

Emergent BioSolutions was arguably one batch away from being a pandemic hero. 
Just months after COVID-19 gripped the world, the Maryland-based life sciences company had locked in deals to manufacture two of the five leading Operation Warp Speed vaccine candidates. 
Shortly after Emergent had inked what eventually became a five-year deal worth at least $480 million with Johnson & Johnson to produce bulk drug substance for Janssen’s vaccine candidate, the U.S. government issued a $628 million task order to reserve capacity for a second OWS innovator — AstraZeneca. This resulted in Emergent signing an additional $261 million deal to make drug substances for the AstraZeneca-Oxford vaccine candidate. 

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

Novavax logo
Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against the Omicron variant as well as additional data from its ongoing Phase 2 boost study. New results demonstrate broad cross-reactivity against Omicron and other circulating variants from a primary 2-dose regimen, with responses that increased following a third dose at six months.

Capital Region Emerges as Undisputed Leader in War on Infectious Diseases

Published on :

With the Delta variant driving over 100,000 new infections per day across the United States, the COVID-19 pandemic is far from over. While COVID continues to rage, infectious disease experts are not only battling the ongoing pandemic but are on the lookout for the next virulent threat.

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax’ seasonal influenza and COVID-19 vaccines. The clinical trial combines Novavax’ recombinant protein-based NVX-CoV2373 and NanoFlu™ vaccine candidates and patented saponin-based Matrix-M™ adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine). Both NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 clinical trials.

ACC’s Smart Solution for a secure data pipeline to support Covid vaccine manufacturing

Published on :

Johnson & Johnson’s pharmaceutical arm, Janssen, embarked on a global effort to combat the COVID-19 pandemic. To support their goal of supplying one billion doses of vaccine, an agreement with a contract manufacturer was reached. Large-scale manufacturing of Janssen’s vaccine would take place at the contract manufacturing site, which is designed for rapid manufacturing of vaccines and other treatments in large quantities during public health emergencies.

Baltimore Sun – Maryland-based Novavax’s effort to vaccinate the world, from zero to not quite warp speed: ‘This takes time and expertise’

Published on :

On a sweltering June morning, Novavax CEO and COVID vaccine maker Stanley Erck stood on a stage unmasked and did something that would have been unthinkable six months ago: He shook hands with Maryland’s governor.

TEDCO and JLABS Discuss Innovation and Workforce Diversity in Maryland

Published on :

TEDCO recently launched ‘TEDCO Talks’, a series featuring thought leaders in economic development across the State of Maryland. On May 28th, TEDCO CEO & Executive Director, Troy LeMaile-Stovall interviewed Sally Allain, Head of JLABS @ Washington DC, about the future of the innovation ecosystem and the crucial role that JLABS will play in advancing the BioHealth Capital Region.